SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items

• SCHOTT Pharma held its Annual General Meeting virtually on February 4, 2025
• All items on the agenda were approved by shareholders
• Dr. Wolfram Carius has been appointed to SCHOTT Pharma’s Supervisory Board, replacing Dr. Wolfgang Wienand

SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, held its Annual General Meeting for FY 2024 today. The virtual Annual General Meeting enabled shareholders to directly interact directly with the Management and Supervisory Boards and ask questions. Together, they reflected on the strong fiscal year 2024, in which SCHOTT Pharma exceeded its targets, including its previously raised revenue guidance, and thus accelerated its trajectory of profitable growth. In 2024, right before celebrating its first anniversary as a publicly listed company, SCHOTT Pharma was promoted to the MDAX, underlining its strong performance during the twelve months since its IPO in 2023. The current environment, including growth opportunities and market challenges was also discussed, highlighting a cautious, but optimistic perspective for FY 2025. All structural market trends that pose growth opportunities are showing ongoing strong dynamics: These include the continued high demand for GLP-1 and mRNA drugs, as well as the ongoing commercialization of ADCs and homecare solutions, supporting the strategic shift of SCHOTT Pharma towards high-value solutions. In total, approximately 97% of the share capital was represented. The shareholders voted in favor of all items on the agenda, including the appointment of Dr. Wolfram Carius to SCHOTT Pharma’s Supervisory Board and the installation of KPMG as the company’s new auditor.

“This year’s Annual General Meeting gave us a great opportunity to look back on another successful year for SCHOTT Pharma, together with our shareholders, and to provide an insight into the months ahead. The confidence expressed by the capital markets underscores that we have set the right course: we will continue our profitable growth trajectory. Our innovative products, global footprint and market position as a trusted partner to leading pharma companies put us in a strong position to successfully address the most important pharma trends,” said Andreas Reisse, CEO of SCHOTT Pharma.

"SCHOTT Pharma is a growth-oriented company. We want our shareholders to participate in our profitable growth and are therefore distributing a dividend of EUR 0.16 per share. Despite a challenging market environment, we are convinced that our strategic focus on high-value solutions will continue to enable sustainable, profitable growth," said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

Actions of the Executive Board and Supervisory Board approved by a large majority

The shareholders approved the actions of the Executive Board of the general partner and the Supervisory Board with a large majority. The Annual General Meeting elected Dr. Wolfram Carius, Executive Vice President of BAYER AG, as a new member of the Supervisory Board. Dr. Wolfram Carius is a well-recognized senior expert in the pharma industry, currently serving as Executive Vice President at BAYER AG and member of the Supervisory Board at Siegfried AG. Former Supervisory Board member Dr. Wolfgang Wienand resigned from his previous position, due to limitations for external mandates at mandates at Lonza AG, where he serves as CEO.

All agenda items received high approval rates

The voting results for each item were as follows:

• Adoption of the annual financial statements as of September 30, 2024, with 99.99% of the votes cast
• Approval of the proposed allocation of distributable profit, including the distribution of a dividend of EUR 0.16 per dividend-bearing share, with 99.99% of the votes cast
• Approval of the actions of the members of the Executive Board of the general partner for the 2024 financial year with 99.53% of the votes cast
• Approval of the actions of the members of the Supervisory Board for the 2024 financial year with 96.34% of the votes cast
• Election of KPMG AG Wirtschaftsprüfungsgesellschaft as auditor for the potential review of the condensed financial statements and the interim management report for fiscal year 2024, and as auditor for the potential audit review of interim financial information for fiscal year 2025 and other interim financial information during the year with 98.99% of the votes cast
• Approval of the remuneration report for the 2024 financial year with 93.12% of the votes cast
• Election of Dr. Wolfram Carius as member of the Supervisory Board, effective February 4, 2025, with 90.69% of the votes cast
• Approval of the conclusion of a profit and loss transfer agreement between the company and SCHOTT Pharma Mexico GmbH with 99.98% of the votes cast

For additional information and documents on the Annual General Meeting of SCHOTT Pharma please visit our investor relations website: https://www.schott-pharma.com/investor-relations/events/annual-general-meeting/

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

Press contact

Lea Kaiser

Media Relations

Tel.: +49 (0) 6131 66 2422

E-Mail: lea.kaiser@schott.com 

Tobias Erfurth

Head of Investor Relations

E-Mail: ir.pharma@schott.com

Jasko Terzic, CFA

Senior Manager Investor Relations

E-Mail: ir.pharma@schott.com